September 3: The Rotation Inside AI — Hardware Gives Back, the Tape Finally Broadens

Market regime

The relief rally stopped being narrow. After weeks of a bifurcated tape that hid its weakness behind an unchanged S&P 500, today breadth turned decisively positive: 3,287 advancers against 1,319 decliners, with the average stock up 0.66%. That is the first day in this stretch where the internals actually confirmed the headline rather than contradicting it. The Goldilocks spine is intact — unemployment 4.10%, sticky CPI 2.72% and easing, the 10Y-2Y spread out to +51bp, VIX dozing at 14.6 — but the more important development is where the money went. This was not an AI-led rally; it was a rally that finally outgrew AI.

Mega forces

1. The AI fabric is being re-priced — down the stack. The capex trade is no longer just stalling; it is decomposing. The former leaders are now the leaders in reverse: optical and networking names CRDO (-27% on the month), CIEN (-22%), Coherent (-19%), AAOI (-22%), and Applied Materials (-18%) are all breaking down, while the application layer is exploding — Atlassian +72%, CRM +37%, Elastic +38%, GitLab +36%, Paycom +38%, Veeva +33%. The marginal AI dollar is rotating from semiconductors and interconnects into software that already monetizes intelligence. Scarcity is migrating from silicon to workflow.

2. The debasement trade keeps broadening. Oil (+22% month) has joined gold and silver as the tape's quiet engine. Energy is the best-performing sector (+12% over one month), with the entire hydrocarbon complex — integrateds, E&Ps, royalty, and oilfield services — occupying four of the top ten themes. Geopolitical supply risk (Iran) is the spark, but the deeper driver is the same real-rate repricing supporting precious metals and crypto: the market is paying up for hard assets and income as long rates hold at multi-decade highs.

3. Biopharma is an emerging leadership pocket. Health Care (+6% month) is the quiet second-place sector, and it is being led by precision oncology — MRNA up ~165% in a month on the first-in-class mRNA cancer-vaccine readout, TEM +38%. This is a fundamentally distinct driver from the macro trades: a genuine clinical-productivity cycle, not a rate story.

What's working

• Application software where AI is already revenue, not roadmap. The blowouts (CRM, TEAM, GTLB, ESTC, PAYC, VEEV) are the new leadership; the spec is earnings acceleration, not multiple expansion.
• Energy and hard-asset income. Oil's move is supported by both supply risk and the fiscal/term-premium backdrop; the integrated/oilfield complex still screens cheap relative to the commodity.
• Precision oncology and biotech with real clinical catalysts. This is the rare pocket with idiosyncratic upside uncorrelated to rates.

What to avoid

• The old AI infrastructure names — optics, networking, and semis equipment (CRDO, CIEN, COHR, AAOI, AMAT). They are still in a downtrend and now carry the double burden of crowded positioning and rising financing costs as capex approaches operating cash flow.
• Industrials and consumer discretionary (-6% month in both). Industrials are the clearest casualty of the debasement/war-risk shock via input costs; discretionary is feeling the consumer-softening story playing out in Lululemon, DKS, and the airlines.

Strategy

Own the application layer of AI and the real-asset income complex (energy, gold/silver miners), and treat biotech as an alpha sleeve. The regime is no longer "buy the AI index" — it is a stock-picker's tape where the re-pricing is happening within AI and toward hard assets. Watch the 10-year (4.63%) and the term premium: while the Fed is on hold at 3.63%, the binding constraint on the crowded growth trade is no longer the Funds rate but the long end, and credibility on the fiscal side is the variable that moves it.